Clinical Trials

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

15 enrolled

Neoplasms, Recurrence

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06637501 2026-02-23

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

94 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06854003 2026-02-20

BRAZAN

60 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

45 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoma, Follicular

NCT07271667 2026-02-13

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

108 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07341191 2026-02-12

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Recurrence, Lymphoma, Mantle-Cell

NCT04463953 2026-02-11

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

25 enrolled

Waldenstrom Macroglobulinemia

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT04116437 2026-01-28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

96 enrolled

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06492837 2026-01-28

FIL_MOZART

56 enrolled

Lymphoma, Follicular

NCT06846463 2026-01-23

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

21 enrolled

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06563505 2026-01-21

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

36 enrolled

Lymphoma

NCT06647732 2026-01-15

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

42 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05952037 2026-01-02

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

114 enrolled

Lymphoma, Waldenstrom Macroglobulinemia

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07261163 2025-12-03

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT06547866 2025-11-26

WAZABI

102 enrolled

Waldenstrom Macroglobulinemia

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06561347 2025-11-24

ZEBRA

55 enrolled

Waldenstrom Macroglobulinemia

NCT06839053 2025-11-19

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05718869 2025-11-04

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

26 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

227 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06849713 2025-09-25

BOSon

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03824483 2025-09-23

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05068440 2025-07-25

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

65 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04515238 2025-06-10

CLL2-BZAG

42 enrolled

Leukemia, B-Cell

NCT07012980 2025-06-10

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07003464 2025-06-04

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06973811 2025-05-20

ZR-MTX

47 enrolled

Intraocular Lymphoma

NCT06959732 2025-05-07

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Lymphoma, Follicular

NCT04460248 2025-05-02

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

59 enrolled

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

NCT05635162 2025-04-16

ZEBRA

50 enrolled

Lymphoma, Mantle-Cell

NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

35 enrolled

Lymphoma, B-Cell

NCT06669143 2024-11-01

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

19 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03145064 2024-10-26

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

41 enrolled 15 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03206918 2024-10-26

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

91 enrolled 14 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

86 enrolled 16 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03520920 2024-10-26

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

41 enrolled 25 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03846427 2024-10-26

MAGNOLIA

68 enrolled 28 charts 1 FDA

Lymphoma, B-Cell, Marginal Zone

NCT06544785 2024-10-24

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

106 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624958 2024-10-18

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

42 enrolled

Lymphoma, Mantle-Cell

NCT05202782 2024-10-16

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06549335 2024-10-15

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

66 enrolled